Open-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Pharmacodynamics
- Sponsors EMD Serono; Newron Sweden AB
- 02 Feb 2012 Actual patient number is 5 according to ClinicalTrials.gov.
- 02 Feb 2012 Planned end date changed from 1 Nov 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 02 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.